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INTRODUCTION
Chronic graft-versus-host disease (GVHD) was first
reported in the 1970s among long-term survivors after
HLA-identical sibling marrow transplantation [1-5]. It has
remained a major determinant of late transplantation-
related morbidity and mortality for the past 30 years.
Chronic GVHD has been observed in 33% of genetically
HLA-identical sibling recipients who survived more than
150 days after transplantation, in 49% of recipients of phe-
notypically HLA-matched related transplants, and in 64%
of recipients of HLA-matched unrelated transplants [6].
Manifestations of chronic GVHD resemble those of
autoimmune systemic collagen vascular diseases, are vari-
able, and include dermatitis, keratoconjunctivitis, general-
ized sicca syndrome, oral mucositis, esophageal and vaginal
strictures, liver disease, pulmonary insufficiency, malab-
sorption, generalized wasting, and recurrent bacterial
infections [1,5-8]. In severe cases, chronic GVHD may be
present as extensive scleroderma-like skin disease with
crippling contractures, and up to 80% of these patients will
die, in most cases due to infections, which develop on the
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ABSTRACT
We analyzed effects of successive changes in prevention and treatment of chronic GVHD in 405 patients with aplas-
tic anemia and refractory anemia given HLA-matched hematopoietic stem cell transplantation (HSCT) from 1970-
1997. For analysis, patients were divided into group I, transplantations from 1970-1976; group II, 1977-1983; group
III, 1984-1990; and group IV, 1991-1997. The overall incidence of chronic GVHD was 28%. Incidences of chronic
GVHD for groups I through IV were 20%, 46%, 41%, and 22%, respectively, reflecting added buffy coat infusions
in groups II and III. Five-year survival rates of patients with chronic GVHD for groups I through IV were 58%,
74%, 82%, and 76%, respectively (NS). Among group I patients, 50% were alive off immunosuppression, none were
alive on immunosuppression, and 50% died. These figures were 76%, 0%, and 24% in group II; 80%, 10%, and 10%
in group III; and 64%, 21%, and 14% in group IV patients. More serious infections and skin contractures were seen
in group I than in groups II, III, and IV (P = .0001, .02, .01 and P =.0003, .001, .05, respectively). Lung complica-
tions, aseptic necroses, depression, and Karnofsky scores were comparable among groups. Gastrointestinal compli-
cations seemed less frequent among groups II through IV. Diabetes mellitus was more frequent in group IV than in
groups I through III (P = .008). Secondary malignancies occurred in 33%, 6%, 3%, and 0% of patients in the 4 groups,
respectively. In conclusion, over 28 years, chronic GVHD has remained challenging, with only slight improvements
in quality of life. Decisive improvements in therapy and survival will have to await both a better understanding of
the immunological events underlying chronic GVHD and better infection prevention and control.
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basis of severe impaired immune function and immunosup-
pressive treatment [4,7-11].
Treatment for extensive chronic GVHD was studied in
a systematic manner beginning in the 1970s [8]. At first,
short courses of antithymocyte globulin (ATG) were
explored, and no improvement of survival was seen. How-
ever, the introduction of combined immunosuppression
with prednisone and either cyclophosphamide, procabazine,
or azathioprine suggested a favorable impact on the adverse
natural course of extensive chronic GVHD [8]. A subse-
quent study compared prednisone and azathioprine with
prednisone and placebo and showed that prednisone alone
resulted in both lower mortality and better survival of
standard-risk patients if treatment was started early in the
course of chronic GVHD [12]. However, for high-risk
GVHD with persistent thrombocytopenia, long-term sur-
vival with prednisone alone was only 26%. Combining
cyclosporine (CSP) with prednisone has been shown to
improve survival in high-risk patients [13]. More recently,
the use of newer immunosuppressive drugs like thalidomide,
FK506, rapamycin, and mycophenolate mofetil (MMF) has
shown promising preliminary results, but these results need to
be veriﬁed in prospective trials [13-19]. Here, we analyzed data
from 405 consecutive patients who received HLA-matched
transplants over a period of 28 years (1970-1997) to deter-
mine the impact of successive changes in both GVHD pre-
vention and treatment on the incidence and morbidity of,
and mortality from, chronic GVHD. For the purposes of
analysis, patients were divided into 4 groups depending on
year of transplantation. The analysis included only patients
with nonmalignant diseases, aplastic anemia and refractory
anemia, to minimize the number of potential confounding
factors, eg, recurrence of malignancy and effects of preced-
ing chemotherapy in patients with malignant diseases.
MATERIALS AND METHODS
Patients
Between 1970 and 1997, 405 consecutive patients with
aplastic anemia or refractory anemia received their ﬁrst mar-
row transplants from HLA-matched siblings at the Fred
Hutchinson Cancer Research Center (FHCRC). Diagnoses
established at the referring institutions were conﬁrmed by
review of outside marrow specimens and repeat marrow aspi-
rates and biopsies. Eighty-three patients either died before
day 100 or received second marrow transplants. Of the
remaining 322 patients, 20 developed limited chronic
GVHD and 113 developed extensive chronic GVHD. This
analysis was restricted to patients with extensive chronic
GVHD. The patients were categorized into 4 groups by year
of transplantation, as follows: group I, 1970-1976; group II,
1977-1983; group III, 1984-1990; group IV, 1991-1997.
These time periods roughly coincided with major changes in
either GVHD prophylaxis, treatment of acute GVHD, treat-
ment of chronic GVHD, the composition of the allografts
(ie, addition and, later, discontinuation of viable donor
peripheral blood mononuclear cells [buffy coat cells] to the
marrow inoculum), or the conditioning regimens (cyclophos-
phamide/ATG). Patient characteristics are summarized in
Table 1. Ninety-eight patients had transplantations for aplas-
tic anemia and 15 for refractory anemia according to French-
American-British (FAB) classiﬁcation. Patients were treated
after outpatient and inpatient conferences that fully outlined
the advantages and disadvantages of transplantation. Treat-
ment protocols and consent forms were approved by the
Institutional Review Board of the FHCRC.
Conditioning Regimens
All but 1 patient received cyclophosphamide, adminis-
tered alone (n = 82) [3] or in combination with either ATG
(n = 15) [20], total body irradiation (n = 5), or busulfan (n = 8)
[21]. Three patients received alternative regimens. Fifty-
four aplastic anemia patients were given marrow and viable
donor buffy coat cells to reduce the risk of graft rejection
[22]. The conditioning regimens used during the different
time periods are shown in Table 1.
GVHD Prophylaxis and Assessment
GVHD prophylaxis consisted of a combination of a
short course of methotrexate (MTX) (15 mg/m2 on day 1
and 10 mg/m2 per day on days 3, 6, and 11) and CSP from
day –1 to day 180 in 47 patients [23], MTX alone (days 1, 3,
6, 11, and 18 and once weekly until day 102) in 54 patients
[3,5], and CSP alone (day –1 to day 180) in 5 patients. Five
patients received steroids in combination with MTX and
CSP [24], and in 2 patients, treatment was changed from
CSP to FK506. Assessment of hematopoietic engraftment
and grading and treatment of acute and chronic GVHD
were performed as previously described [7,8,23]. Posttrans-
plantation supportive care has been described [20].
Long-term Follow-up
All patients underwent a departure work-up at 3 months
after transplantation [25] and returned to the FHCRC at
1 year and sporadically thereafter for complete evaluations.
Follow-ups consisted of contacts every 6 months initially
and, later, annual contacts with the physicians’ offices and
mailing of questionnaires to physicians to obtain objective
data. If no responses were received within 2 months, second
letters were mailed.
Patients were contacted once yearly on their transplan-
tation anniversaries and, beginning in August 1990, were
mailed annual questionnaires. The patients’ responses sup-
plemented results obtained from physicians and provided
self-assessments of performance and well-being using visual
analog scales.
Information about posttransplantation courses with
respect to GVHD and its treatment, infections, complica-
tions, and deaths was obtained by reviewing medical histo-
ries of patients at their yearly examinations, notes of phone
conversations with the patients, annual patient and physi-
cian questionnaires, and other records mailed to us by pri-
mary physicians.
Infections
Multiple infections in a given patient appearing in the
same narrow time frame and being caused by the same
pathogens were counted as a single infectious event. All
infections were recorded and valued equally to demonstrate
general morbidity in these patients. A more informative
analysis focused on septicemia, meningitis, and pneumonia,
because these serious infections were usually associated with
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higher morbidity and mortality than were others. Sep-
ticemia was defined as 1 positive blood culture for any
organism associated with either hypotension or a documented
local infection caused by the same organism recovered
from the blood.
Other Complications
To analyze the frequency of GVHD or GVHD treat-
ment–related complications, we determined in each patient
group how many complications per patient developed. For
the purpose of this analysis, we grouped scleroderma, con-
tractures, skin ulcers, and alopecia together as skin compli-
cations. Lung complications included all cases of chronic
obstructive lung disease and bronchiolitis obliterans as man-
ifested by impaired performance or by pulmonary function
tests at levels less than 80% of predicted. Gastrointestinal
complications included all events of strictures, ulcers, and
perforations that occurred at any part of the gastrointestinal
tract. Other complications included depression requiring
therapy or indicated by suicide attempts, diabetes mellitus
requiring therapy, cataracts diagnosed incidentally or
because of visual impairment, avascular necroses with or
without joint replacement, and secondary malignancies
developing after transplantation. We also ascertained
whether female patients delivered children or male patients
fathered children.
Statistics
The probability of chronic GVHD was estimated as a
simple proportion among all patients and among those who
survived without second transplants to day 100, as it was
assumed that all patients had complete follow-up with
respect to development of chronic GVHD. The hazard of
chronic GVHD was compared between patient groups by
ﬁtting a Cox regression model.
Survival estimates were obtained from the method of
Kaplan and Meier, and the hazard of death was compared
between groups by fitting Cox regression models. Time
zero for each of these models was taken to be the date of
transplantation, and the model for the hazard of mortality
considered the data to be left truncated, in that patients did
not enter the risk set for mortality until chronic GVHD
occurred. The impact of chronic GVHD on the hazard of
mortality during each time period was assessed by considering
Table 1. Demographic Data and Transplant Characteristics of Patients Who Developed Extensive Chronic GVHD
Date
1970-1976 1977-1983 1984-1990 1991-1997
n 12 54 33 14
Patient age, y
Median 16 22 27 46
Range 4-41 7-42 5-49 31-63
Diagnosis, no. of patients
Refractory anemia 0 0 6 9
Aplastic anemia
Total 12 54 27 5
Idiopathic 10 41 22 4
Chemical/drug 2 5 1 1
Genetic 0 4 2 0
Hepatitis 0 2 1 0
Paroxysmal nocturnal hemoglobinuria 0 0 1 0
Others 0 2 0 0
Sex of donor/patient, no. of patients
M/M 4 18 10 2
M/F 1 14 4 4
F/M 5 13 11 5
F/F 2 9 8 3
Donor age, y
Median 18 18 24 44
Range 3-52 6-44 3-58 29-62
Conditioning, no. of patients
Cyclophosphamide alone 11 10 7 0
Cyclophosphamide + ATG 0 0 10 5
Cyclophosphamide + TBI 0 0 3 2
Cyclophosphamide + buffy coat 0 42 12 0
Cyclophosphamide + busulfan 0 0 1 7
Other 1 2 0 0
GVHD prophylaxis, no. of patients
MTX alone 12 40 2 0
MTX + cyclosporine 0 10 26 11
Cyclosporine alone 0 4 0 1
MTX + cyclosporine + steroids 0 0 5 0
MTX + Cyclosporine → FK 506 0 0 0 2
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GVHD as a time-dependent covariate. Time zero for this
latter analysis was date of transplantation.
The probability of discontinuing immunosuppressive
treatment according to time following GVHD and the
probability of dying during continued immunosuppression
were each estimated by using cumulative incidence esti-
mates, in which one event was considered as a competing
risk for the other event. The hazards of discontinuing
immunosuppression and of dying while on immunosuppres-
sion were compared by ﬁtting Cox regression models.
The probabilities of complications that could occur
once, at most, were estimated by using cumulative inci-
dence estimates, in which death without the appropriate
complication was considered a competing risk. The hazards
of the appropriate complications were compared through
Cox regression models. Infection rates and rates of compli-
cations that could occur more than once were compared by
using Poisson regression, in which rates were estimated by
counting the number of infections (or complications) and
normalizing by the number of years at risk. A patient was
considered to be at risk from the time of GVHD to last
contact or a fixed time that was prespecified. Data were
analyzed as of October 1999.
All reported P-values are 2-sided, and those associated
with regression models were estimated from the Wald test.
No adjustments were made for multiple comparisons.
RESULTS
Incidences of Chronic GVHD 
The probability for developing extensive chronic GVHD
was close to 50% for patients receiving transplants from
1977-1983 and from 1984-1990 compared to approximately
25% for patients receiving transplants from 1970-1976 and
from 1991-1997 (Figure 1). Compared to 1970-1976, the
hazard of extensive GVHD was higher during time periods
1977-1983 and 1984-1990 (hazard ratio [HR] = 2.4, 95%
conﬁdence interval [CI] 1.3-4.5, P = .006; and HR = 2.0, 95%
CI 1.1-3.9, P = .04, respectively), but similar in 1991-1997
(HR = 1.0, 95% CI 0.5-2.1, P = .94). During 1977-1990,
transfused patients received viable buffy coat infusions in
addition to the marrow grafts to reduce the risk of graft rejec-
tion [22], and this accounted for the increase in chronic
GVHD [4]. The median times to diagnosis of extensive
chronic GVHD were 182, 166, 169, and 121 days, respec-
tively, for the 4 groups (Table 2).
Types of Chronic GVHD 
In 56 of the 113 patients, acute GVHD directly pro-
gressed to chronic GVHD (progressive onset); in 10 patients,
acute GVHD had resolved before development of chronic
GVHD (quiescent onset); and in 47 patients, chronic
GVHD developed without signs of preceding acute GVHD
(de novo onset) (Table 2). The numbers of patients with de
novo onset were particularly high from 1977-1983 and
1984-1990, during which time transfused patients received
added donor buffy coat infusions.
Survival 
Surviving patients have been followed for 2 to 27 years.
Thirty-seven of the 113 patients who developed extensive
chronic GVHD died (Figure 2, Table 3). Twenty-seven of
these deaths were related to chronic GVHD or its treat-
ment. Seven patients died because of reasons not related to
GVHD, primarily cardiac disease. For 3 patients, causes of
death could not be determined. Median times from diagno-
sis of chronic GVHD to death did not differ signiﬁcantly in
the 4 groups, whereas the case fatality rates decreased from
58% to 14% (Table 3).
Although the probabilities of survival for patients with
chronic GVHD were not statistically signiﬁcantly different
among the 4 patient groups (global P = .37; Figure 2), the
HRs of death (hazard of death among patients with chronic
GVHD compared to hazard of death among patients with-
out GVHD) decreased from 5.5 in 1970-1976 to 1.8 in
Figure 1. Overall incidence of extensive chronic GVHD. Probabilities
among aplastic anemia and refractory anemia patients surviving beyond
day 100 after matched sibling transplants between 1970 and 1997.
Results are shown for 4 different time periods: 1970-1976, 1977-1983,
1984-1990, and 1991-1997.
Table 2. GVHD-Related Data of Patients Who Developed Extensive
Chronic GVHD
Date
1970-1976 1977-1983 1984-1990 1991-1997
Acute GVHD, 
no. of patients (%)
Grade 0 3 (25) 21 (39) 20 (61) 3 (22)
Grade 1 0 (0) 9 (17) 3 (9) 1 (7)
Grade 2 3 (25) 9 (17) 5 (15) 8 (57)
Grade 3 5 (42) 12 (22) 5 (15) 2 (14)
Grade 4 1 (8) 3 (5) 0 (0) 0 (0)
Types of chronic GVHD, 
no. of patients (%)
Progressive 9 (75) 29 (54) 11 (33) 7 (50)
Quiescent 0 (0) 4 (7) 2 (6) 4 (28)
De novo 3 (25) 21 (39) 20 (61) 3 (22)
Time to GVHD, d
Mean 205 202 191 134
Median 182 166 169 121
Range 98-421 83-957 79-528 83-265
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1990-1997 (Table 4), suggesting that the impact of extensive
chronic GVHD on survival has become less important in
recent years.
Treatment
A total of 103 patients received treatment for chronic
GVHD. Among the remaining 10 patients, 1 died on the
day of diagnosis of chronic GVHD, 2 died shortly after
diagnosis, 5 were not compliant with study medications, and
for 2 patients, treatment data were missing. Most patients
were included in phase II or phase III clinical trials aimed at
improving treatment for chronic GVHD.
The single agents and drug combinations used for treat-
ing chronic GVHD are listed in Table 5. Patients receiving
transplants between 1970 and 1976 received mainly steroids
(33%) or ATG (20%) as single agents or combinations of
steroids with azathioprine (17%) or cyclophosphamide
(10%). Most patients who received transplants during 1977-
1983 received steroids (34%) or azathioprine (10%) alone or
in combination (26%). Patients in group III (1984-1990)
were mainly treated with steroids (27%), CSP (11%), a
combination of steroids and CSP (29%), or a combination
of steroids and azathioprine (11%). For the time period
1990-1997, CSP was the mainstay of treatment, used either
alone (15%) or in combination with steroids (55%).
In 51 of the 103 patients (49.5%), primary treatment
was not successful. Additional treatments were needed in
50% of group I patients, 46% of group II patients, and 42%
of both groups III and IV patients. Further analyses showed
that patients in group I were given a mean of 2.6 treatment
courses (range, 0-6), patients in both groups II and III
required a mean of 1.9 treatment courses (range, 0-6), and
patients in group IV received a mean of 1.4 (range, 1-2)
treatment courses. Differences between the groups were not
statistically signiﬁcant.
Duration of Immunosuppressive Therapy
Most of the surviving patients with chronic GVHD
became treatment independent [26]. Figure 3 depicts the
probability of being alive and discontinuing immunosup-
pression together with the probability of dying during con-
tinued immunosuppression for each patient group. The area
between the 2 curves represents patients who were alive
with continued immunosuppression.
The hazards of discontinuing immunosuppression were
statistically significantly different among the 4 groups
(global P = .005), whereas the hazards of dying while receiv-
ing immunosuppressive treatment were not statistically
signiﬁcantly different among the 4 groups (global P = .32).
In particular, the hazard of discontinuing immunosuppres-
sive therapy among patients receiving transplants in 1977-
1983 was 4.7 times greater than the hazard among patients
Figure 2. Probability of survival of patients with extensive chronic
GVHD. Results are shown for 4 different time periods: 1970-1976,
1977-1983, 1984-1990, and 1991-1997. Causes of deaths after 10 years
included squamous cell carcinoma (n = 3), cardiac arrest (n = 2), and
unknown (n = 1).
Table 3. Mortality and Causes of Death
Date
1970-1976 1977-1983 1984-1990 1991-1997
Mortality 7/12 20/54 7/33 3/14
No. of chronic GVHD–related deaths (%) 7 (58) 14 (26) 4 (12) 2 (14)
Septicemia 4 4 1 1
Pneumonia 1 5 0 1
Secondary malignancy 2 1 0 0
Bleeding 0 0 0 0
Viral infection 0 3 0 0
Bronchiolitis obliterans 0 1 2 0
Drug side effects 0 0 1 0
No. of deaths unrelated to chronic GVHD 0 6 3 1
Cardiac 0 4 0 0
Idiopathic pulmonary fibrosis 0 1 0 0
Human immunodeficiency virus 0 0 1 0
Bone marrow failure 0 0 1 0
Unknown 0 1 1 1
Days from diagnosis of chronic GVHD to death
Median 709 672 906 306
Range 244-6617 107-5175 129-3331 219-523
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receiving transplants in 1970-1976 (P = .01). Compared to
this same group, the hazards among patients receiving trans-
plants in 1984-1990 (HR = 4.2, P = .02) and among patients
receiving transplants in 1991-1997 (HR = 10.1, P = .001)
were also significantly higher. Patients had immunosup-
pression discontinued at a median of 2126 days in group I,
compared to medians of 665 days in group II, 483 days in
group III, and 280 days in group IV. The differences in
treatment durations were not statistically signiﬁcant.
Infections
A total of 628 episodes of infections were recorded for
the 113 patients with extensive chronic GVHD. The mean
rates of all infections between days 100 and 360 per year of
follow-up were 4.64 for patients in group I, 2.81 for
patients in group II, 5.53 for patients in group III, and 5.05
for patients in group IV. No groups were statistically
signiﬁcantly different from the 1970-1976 cohort, with the
exception of group II (lower; P = .007). However, overall
infections between days 360 and 1080 per year of follow-up
were significantly more common in patients receiving
transplants from 1970-1976 (mean, 2.16) than in those
from 1977-1983 (mean, 1.10; P < .0001), 1984-1990 (mean,
1.34; P = .02), and 1991-1997 (mean, 0.59; P = .01) (Figure 4).
For infections occurring beyond 3 years after transplanta-
tion, the mean rates per year of follow-up were similar
among the 4 groups (0.17, 0.84, 0.32, 0.09).
Serious infections (septicemias, pneumonias, and menin-
gitis) between days 360 and 1080 occurred at a mean rate of
0.84 in patients in group I, which was statistically signifi-
cantly higher than rates for patients in groups II (0.33; P <
.0001), III (0.26; P < .0004), and IV (0.16; P = .04) (Figure 4).
Beyond 3 years after transplantation, mean rates of serious
infections did not differ signiﬁcantly between the 4 groups.
Other Complications
The mean rates for various complications among the
4 groups per year at risk are summarized in Figure 5. Skin
complications were signiﬁcantly reduced in patients of groups
II through IV compared to those of group I (P = .0003, P =
.001, and P = .05, respectively). Similar trends were seen for
gastrointestinal complications, but the numbers of events
were too small to fit a valid regression model. Pulmonary
complications were not statistically significantly different
Table 4. Hazard of Death Among Patients With Chronic GVHD Com-
pared to the Hazard of Death Among Patients Without GVHD
Years of Transplantation Hazard Ratio 95% CI P Value
1970-1976
Patients without GVHD 1 — —
Patients with GVHD 5.5 1.9-15.8 .001
1977-1983
Patients without GVHD 1 — —
Patients with GVHD 1.9 1.0-3.6 .05
1984-1990
Patients without GVHD 1 — —
Patients with GVHD 2.7 0.9-8.0 .08
1991-1997
Patients without GVHD 1 — —
Patients with GVHD 1.8 0.5-6.8 .38
Table 5. Treatments Used in Patients With Extensive Chronic GVHD*
Therapy for Chronic GVHD 1970-1976 1977-1983 1984-1990 1991-1997
Single agent
ATG 6 0 0 0
Steroids 10 33 17 1
Cyclophosphamide 1 3 0 0
Cyclosporine 0 2 7 3
Procarbazine 1 3 0 0
Azathioprine 1 10 4 0
Rapamycin 0 0 0 1
Electron beam irradiation 1 0 0 0
Combination therapy
Steroids + cyclophosphamide 3 5 1 0
Steroids + azathioprine 5 25 7 0
Steroids + ATG 1 1 0 0
Steroids + procarbazine 1 6 0 0
Steroids + MTX 0 1 0 0
Steroids + cyclosporine 0 8 18 11
Cyclosporine + azathioprine 0 0 3 0
Cyclosporine + azathioprine + steroids 0 0 1 0
Steroids + azathioprine + PUVA 0 0 1 0
Azathioprine + PUVA 0 0 1 0
Steroids + PUVA 0 0 1 0
Cyclosporine + thalidomide + steroids 0 0 0 1
Cyclosporine + MMF 0 0 0 1
Cyclosporine + MMF + steroids 0 0 0 1
FK 506 + thalidomide + steroids 0 0 0 1
*PUVA indicates psoralen and UVA.
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among the 4 patient groups. For 3 other GVHD and/or
treatment-related complications, the incidence curves are
shown in Figure 6. The differences for aseptic necroses and
depression were not statistically signiﬁcant, whereas diabetes
occurred signiﬁcantly more often in group IV than in groups
I (P = .09) and II (P = .003), but not group III (P = .11). Sec-
ondary malignancies occurred in 4 patients in group I (33%),
compared to 3 patients in group II (6%), 1 patient in group
III (3%), and none in group IV. No children were born to
patients of groups I and IV, 19 children were born to those of
group II, and 7 children were born to those of group III.
Karnofsky scores and results on work status were not
signiﬁcantly different between the groups (data not shown).
DISCUSSION
The early years of hematopoietic stem cell transplanta-
tion for aplastic anemia and refractory anemia were charac-
terized by 4 problems that adversely affected outcome: graft
rejection [27], cytomegalovirus (CMV) infection [28], acute
GVHD [29], and chronic GVHD [1-8]. Mortality associ-
ated with these problems resulted in survival rates of only
35% to 45% [3,5]. Modiﬁcations in blood transfusion sup-
port [30] and more effective conditioning regimens have
made graft rejection a rare complication [20,22,31,32].
Monitoring of CMV reactivation and prevention of CMV
disease with prophylactic therapies have virtually eliminated
mortality from CMV infection [33-35]. Incidence and sever-
ity of and mortality from acute GVHD have been signiﬁ-
cantly decreased by the introduction of newer immunosup-
pressive drug regimens [23]. As a result, most recent survival
rates have been close to 90% [20,32,36].
Although progress in 3 of the 4 problem areas has been
remarkable and transplantation outcome has improved, the
frequency with which chronic GVHD has been diagnosed
has remained virtually unchanged over the 28-year period of
the current retrospective study. An exception was the dou-
bling in the chronic GVHD incidence in the years 1977-
1990 compared to 1970-1976 and 1991-1997, which can be
explained by the addition of viable buffy coat infusions to the
marrow grafts in multiply transfused patients during that
time, an intervention which successfully served to decrease
the rejection incidence [22]. Buffy coat infusions have not
been used since 1988, and patients receiving transplants in
the 1990s faced a risk of developing chronic GVHD that was
similar to that of patients receiving transplants in the early
1970s, approximately 20% to 25%. Moreover, the case mor-
tality rate associated with chronic GVHD was comparable
over the 4 time periods studied, on average 24%.
These findings have raised the legitimate question of
“what gains have there been in treatment of chronic
GVHD over the past 3 decades?” The answer is “perhaps
some.” First, recipients receiving transplants more recently
have been older. Increasing patient age has been described
as a risk factor for developing chronic GVHD [4,37], and
this should have resulted in more chronic GVHD than is
actually seen in the latest cohort of patients. Second,
assuming that chronic GVHD is caused by immune reac-
tions against minor histocompatibility antigens, it could be
argued that patients with the greatest minor antigen dispar-
ities were previously not at risk for chronic GVHD because
they died from complications associated with both graft
rejection and acute GVHD. Thus, given that most recent
patients neither rejected their grafts nor developed fatal
acute GVHD, a larger proportion of recent patients should
be at risk for developing chronic GVHD. That an increase
in chronic GVHD was not seen might be attributable to
better GVHD prevention. Third, although probabilities of
survival among patients with chronic GVHD were not
significantly different among the 4 groups of patients,
Figure 3. Death and duration of immunosuppression. Probabilities of
death during continued immunosuppressive therapy and probabilities
to discontinue immunosuppression among 113 patients with extensive
chronic GVHD. The area between the 2 curves represents patients
alive but still receiving immunosuppressive therapy for chronic
GVHD. Results are shown for 4 different time periods: 1970-1976,
1977-1983, 1984-1990, and 1991-1997.
recent patients (1991-1997) had their immunosuppressive
therapy discontinued within 2 years of diagnosis of chronic
GVHD, a time point reached by previous transplantation
patients only after 8 to 20 years. Fourth, recent patients had
less frequent skin contractures and gastrointestinal compli-
cations, suggesting that current immunosuppressive treat-
ment regimens were more effective than previous ones.
Alternatively, therapy in recent patients might have been
initiated more promptly, given a greater awareness of
chronic GVHD on the part of physicians. Finally, serious
infections were less frequent in recent patients, and this
might be the result of both better infection prevention and
shortened courses of immunosuppressive therapy.
Almost all patients of the present retrospective analysis
were enrolled in protocol studies aimed at improving treat-
ment of chronic GVHD. In the course of consecutively per-
formed phase III studies, the combination of steroids and
CSP emerged as the most effective therapeutic regimen and
has become a standard for first-line treatment of chronic
GVHD at many transplantation centers [6,13,38,39]. But
many issues regarding the optimal use of this regimen are
still unsolved, including when to start patients on immuno-
suppression, how long to continue therapy, when to taper
the immunosuppression, and which drugs to use in addition
to CSP to control specific manifestations of the disease.
Overall, current treatment regimens have failed to prevent
mortality in one fourth of patients with chronic GVHD.
Therefore, the potential roles of recently introduced drugs,
such as thalidomide, rapamycin, mycophenolate mofetil,
hydroxychloroquin, and others, in the therapy of chronic
GVHD need to be evaluated in controlled randomized trials
[14,16,40-42].
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Figure 4. Early and late infections in GVHD patients. The columns on the left show all infections occurring between 1 to 3 years and beyond 3
years after marrow transplantation. The columns on the right show episodes of pneumonia, septicemia, and meningitis. Mean rate represents the
average of the mean numbers of infections divided by years of follow-up for each time period.
Figure 5. Complications of GVHD. Bars represent mean rates of events per group. Skin complications include contractures, scleroderma, ulcers,
and alopecia. Gastrointestinal complications are perforations, ulcers, and strictures of any part of the gastrointestinal tract. Lung complications are
chronic obstructive lung disease and proven diagnosis of bronchiolitis obliterans.
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Whereas many patients may require multiple courses of
immunosuppression to achieve disease control, others may
be overtreated, given the absence of a reliable prognostic
grading system, which might allow for more speciﬁc therapy
[43]. A recently proposed new staging system for chronic
GVHD might be helpful in that regard, allowing clinicians
to separate those patients who might beneﬁt from reduced
treatment from those who might require more intense
immunosuppression [44].
In conclusion, there have been reductions in the overall
incidence of infectious complications and skin contractures
with the introduction of newer treatment regimens for
chronic GVHD patients. Decisive improvements in survival
will have to await both a better understanding of the
immunological events underlying chronic GVHD, which, in
turn, might result in better therapy for chronic GVHD, and
better prevention and control of infections.
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